Elizabeth S Barrie1, David Weinshenker1, Anurag Verma1, Sarah A Pendergrass1, Leslie A Lange1, Marylyn D Ritchie1, James G Wilson1, Helena Kuivaniemi1, Gerard Tromp1, David J Carey1, Glenn S Gerhard1, Murray H Brilliant1, Scott J Hebbring1, Joseph F Cubells1, Julia K Pinsonneault1, Greg J Norman1, Wolfgang Sadee2. 1. From the Center for Pharmacogenomics, College of Medicine, The Ohio State University, Columbus (E.S.B., J.K.P., W.S.); Department of Human Genetics, Emory University School of Medicine, Atlanta, GA (D.W., J.F.C.); Center for Systems Genomics, Pennsylvania State University, University Park (A.V., S.A.P., M.D.R.); Department of Genetics, University of North Carolina School of Medicine, Chapel Hill (L.A.L.); Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson (J.G.W.); The Sigfried and Janet Weis Center for Research, Geisinger Health System, Danville, PA (H.K., G.T., D.J.C.); Institute for Personalized Medicine, The Pennsylvania State University College of Medicine, Hershey (G.S.G.); Center for Human Genetics, Marshfield Clinic Research Foundation, WI (M.H.B., S.J.H.); and Department of Psychology, The University of Chicago, IL (G.J.N.). 2. From the Center for Pharmacogenomics, College of Medicine, The Ohio State University, Columbus (E.S.B., J.K.P., W.S.); Department of Human Genetics, Emory University School of Medicine, Atlanta, GA (D.W., J.F.C.); Center for Systems Genomics, Pennsylvania State University, University Park (A.V., S.A.P., M.D.R.); Department of Genetics, University of North Carolina School of Medicine, Chapel Hill (L.A.L.); Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson (J.G.W.); The Sigfried and Janet Weis Center for Research, Geisinger Health System, Danville, PA (H.K., G.T., D.J.C.); Institute for Personalized Medicine, The Pennsylvania State University College of Medicine, Hershey (G.S.G.); Center for Human Genetics, Marshfield Clinic Research Foundation, WI (M.H.B., S.J.H.); and Department of Psychology, The University of Chicago, IL (G.J.N.). wolfgang.sadee@osumc.edu.
Abstract
RATIONALE: Dopamine β-hydroxylase (DBH) catalyzes the conversion of dopamine to norepinephrine in the central nervous system and peripherally. DBH variants are associated with large changes in circulating DBH and implicated in multiple disorders; yet causal relationships and tissue-specific effects remain unresolved. OBJECTIVE: To characterize regulatory variants in DBH, effect on mRNA expression, and role in modulating sympathetic tone and disease risk. METHODS AND RESULTS: Analysis of DBH mRNA in human tissues confirmed high expression in the locus coeruleus and adrenal gland, but also in sympathetically innervated organs (liver>lung>heart). Allele-specific mRNA assays revealed pronounced allelic expression differences in the liver (2- to 11-fold) attributable to promoter rs1611115 and exon 2 rs1108580, but only small differences in locus coeruleus and adrenals. These alleles were also associated with significantly reduced mRNA expression in liver and lung. Although DBH protein is expressed in other sympathetically innervated organs, mRNA levels were too low for analysis. In mice, hepatic Dbh mRNA levels correlated with cardiovascular risk phenotypes. The minor alleles of rs1611115 and rs1108580 were associated with sympathetic phenotypes, including angina pectoris. Testing combined effects of these variants suggested protection against myocardial infarction in 3 separate clinical cohorts. CONCLUSIONS: We demonstrate profound effects of DBH variants on expression in 2 sympathetically innervated organs, liver and lung, but not in adrenals and brain. Preliminary results demonstrate an association of these variants with clinical phenotypes responsive to peripheral sympathetic tone. We hypothesize that in addition to endocrine effects via circulating DBH and norepinephrine, the variants act in sympathetically innervated target organs.
RATIONALE: Dopamine β-hydroxylase (DBH) catalyzes the conversion of dopamine to norepinephrine in the central nervous system and peripherally. DBH variants are associated with large changes in circulating DBH and implicated in multiple disorders; yet causal relationships and tissue-specific effects remain unresolved. OBJECTIVE: To characterize regulatory variants in DBH, effect on mRNA expression, and role in modulating sympathetic tone and disease risk. METHODS AND RESULTS: Analysis of DBH mRNA in human tissues confirmed high expression in the locus coeruleus and adrenal gland, but also in sympathetically innervated organs (liver>lung>heart). Allele-specific mRNA assays revealed pronounced allelic expression differences in the liver (2- to 11-fold) attributable to promoter rs1611115 and exon 2 rs1108580, but only small differences in locus coeruleus and adrenals. These alleles were also associated with significantly reduced mRNA expression in liver and lung. Although DBH protein is expressed in other sympathetically innervated organs, mRNA levels were too low for analysis. In mice, hepatic Dbh mRNA levels correlated with cardiovascular risk phenotypes. The minor alleles of rs1611115 and rs1108580 were associated with sympathetic phenotypes, including angina pectoris. Testing combined effects of these variants suggested protection against myocardial infarction in 3 separate clinical cohorts. CONCLUSIONS: We demonstrate profound effects of DBH variants on expression in 2 sympathetically innervated organs, liver and lung, but not in adrenals and brain. Preliminary results demonstrate an association of these variants with clinical phenotypes responsive to peripheral sympathetic tone. We hypothesize that in addition to endocrine effects via circulating DBH and norepinephrine, the variants act in sympathetically innervated target organs.
Authors: Jordan G Wood; Peter R Joyce; Allison L Miller; Roger T Mulder; Martin A Kennedy Journal: Biol Psychiatry Date: 2002-03-01 Impact factor: 13.382
Authors: C Depondt; H R Cock; D G Healy; M W Burley; D Weinshenker; N W Wood; D B Goldstein; S M Sisodiya Journal: Neurology Date: 2004-10-26 Impact factor: 9.910
Authors: C P Zabetian; G M Anderson; S G Buxbaum; R C Elston; H Ichinose; T Nagatsu; K S Kim; C H Kim; R T Malison; J Gelernter; J F Cubells Journal: Am J Hum Genet Date: 2001-01-19 Impact factor: 11.025
Authors: Kenji Yamamoto; Joseph F Cubells; Joel Gelernter; Chawki Benkelfat; Pierre Lalonde; David Bloom; Samarthji Lal; Alain Labelle; Gustavo Turecki; Guy A Rouleau; Ridha Joober Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2003-02 Impact factor: 3.568
Authors: Xuefeng Zhang; David A Nielsen; Coreen B Domingo; Daryl I Shorter; Ellen M Nielsen; Thomas R Kosten Journal: Addict Biol Date: 2018-03-02 Impact factor: 4.280
Authors: Elizabeth S Barrie; Julia K Pinsonneault; Wolfgang Sadee; Jill A Hollway; Benjamin L Handen; Tristram Smith; L Eugene Arnold; Eric Butter; Emily Hansen-Kiss; Gail E Herman; Michael G Aman Journal: J Dev Phys Disabil Date: 2018-03-05
Authors: Rong Lu; Ryan M Smith; Michal Seweryn; Danxin Wang; Katherine Hartmann; Amy Webb; Wolfgang Sadee; Grzegorz A Rempala Journal: BMC Genomics Date: 2015-08-01 Impact factor: 3.969
Authors: Joseph F Cubells; Jason P Schroeder; Elizabeth S Barrie; Daniel F Manvich; Wolfgang Sadee; Tiina Berg; Kristina Mercer; Taylor A Stowe; L Cameron Liles; Katherine E Squires; Andrew Mezher; Patrick Curtin; Dannie L Perdomo; Patricia Szot; David Weinshenker Journal: PLoS One Date: 2016-05-05 Impact factor: 3.240